---
input_text: 'The role of vagus nerve stimulation in genetic etiologies of drug-resistant
  epilepsy: a meta-analysis. OBJECTIVE: Drug-resistant epilepsy (DRE) affects many
  children. Vagus nerve stimulation (VNS) may improve seizure control; however, its
  role in children with genetic etiologies of epilepsy is not well described. The
  authors systematically reviewed the literature to examine the effectiveness of VNS
  in this cohort. METHODS: In January 2021, the authors performed a systematic review
  of the PubMed/MEDLINE, SCOPUS/Embase, Cochrane, and Web of Science databases to
  investigate the impact of VNS on seizure outcomes in children with genetic etiologies
  of epilepsy. Primary outcomes included seizure freedom rate, >= 90% seizure reduction
  rate, and >= 50% seizure reduction rate. Secondary outcomes were seizure severity
  and quality of life (QOL), including cognitive, functional, and behavioral outcomes.
  A random-effects meta-analysis was performed. RESULTS: The authors identified 125
  articles, of which 47 with 216 nonduplicate patients were analyzed. Common diagnoses
  were Dravet syndrome (DS) (92/216 patients [42.6%]) and tuberous sclerosis complex
  (TSC) (63/216 [29.2%]). Seizure freedom was not reported in any patient with DS;
  the pooled proportion (95% CI) of patients with >= 50% seizure reduction was 41%
  (21%-58%). Secondary cognitive outcomes of VNS were variable in DS patients, but
  these patients demonstrated benefits in seizure duration and status epilepticus.
  In TSC patients, the pooled (95% CI) seizure freedom rate was 40% (12%-71%), >=
  90% seizure reduction rate was 31% (8%-56%), and >= 50% reduction rate was 68% (48%-91%).
  Regarding the secondary outcomes of VNS in TSC patients, several studies reported
  decreased seizure severity and improved QOL outcomes. There was limited evidence
  regarding the use of VNS to treat patients with other genetic etiologies of epilepsy,
  such as mitochondrial disease, Rett syndrome, Doose syndrome, Landau-Kleffner syndrome,
  Aicardi syndrome, Angelman syndrome, ring chromosome 20 syndrome, and lissencephaly;
  variable responses were reported in a limited number of cases. CONCLUSIONS: The
  authors conducted a systematic review of VNS outcomes in children with genetic etiologies
  of DRE. Among the most studied conditions, patients with TSC had substantial seizure
  reduction and improvements in QOL, whereas those with DS had less robust seizure
  reduction. Increased testing, diagnosis, and long-term follow-up studies are necessary
  to better characterize VNS response in these children.'
raw_completion_output: |-
  primary_disease: Drug-resistant epilepsy (DRE)

  medical_actions: Vagus nerve stimulation (VNS); Systematic review; Meta-analysis; Seizure control; Seizure freedom; Seizure reduction; Review of seizure severity; Quality of life assessment

  symptoms: Seizure; Seizure severity; Status epilepticus

  chemicals: 

  action_annotation_relationships: Vagus nerve stimulation (VNS) TREATS seizure IN Drug-resistant epilepsy (DRE); Vagus nerve stimulation (VNS) TREATS seizure severity IN Drug-resistant epilepsy (DRE); Vagus nerve stimulation (VNS) TREATS status epilepticus IN Drug-resistant epilepsy (DRE)
prompt: |+
  From the text below, extract the following entities in the following format:

  subject_extension: <A chemical or drug mentioned in the relationship between the medical action and the symptom, for example, "analgesic agent therapy" has the aspect "analgesic">
  object_extension: <An optional term describing some specific aspect of the object, e.g. "analgesic agent therapy" has the aspect "analgesic">
  subject: <The medical action. For example: blood transfusion, radiation therapy, cardiac catheterization, pulse oximetry, otoscopy>
  predicate: <The relationship type between the medical action and the symptom, usually TREATS or PREVENTS.>
  object: <A sign or symptom associated with the disease and targeted by the medical action. For example, Low serum calcitriol, hypoplasia of the thymus, chronic cough, aortic stiffness, low pulse pressure>
  qualifier: <The primary disease the relationship is about, or specifically the disease the symptom is related to. For example, Beck-Fahrner syndrome, hereditary retinoblastoma, progeria, diabetes mellitus, infectious otitis media>
  subject_qualifier: <An optional qualifier or modifier for the subject of the statement, e.g. "high dose" or "intravenously administered">
  object_qualifier: <An optional qualifier or modifier for the object of the statement, e.g. "severe" or "with additional complications">


  Text:
  Vagus nerve stimulation (VNS) TREATS status epilepticus IN Drug-resistant epilepsy (DRE)

  ===

extracted_object:
  primary_disease: Drug-resistant epilepsy (DRE)
  medical_actions:
    - MAXO:0000942
    - Systematic review
    - Meta-analysis
    - Seizure control
    - Seizure freedom
    - Seizure reduction
    - Review of seizure severity
    - Quality of life assessment
  symptoms:
    - HP:0001250
    - Seizure severity
    - HP:0002133
  action_annotation_relationships:
    - subject: <Vagus nerve stimulation>
      predicate: <TREATS>
      object: <seizure>
      qualifier: <Drug-resistant epilepsy>
      subject_qualifier: <null>
      object_qualifier: <null>
      subject_extension: <Vagus nerve stimulation>
      object_extension: <null>
    - subject: MAXO:0000942
      predicate: TREATS
      object: seizure severity
      qualifier: Drug-resistant epilepsy (DRE)
    - subject: MAXO:0000942
      predicate: TREATS
      object: HP:0002133
      qualifier: Drug-resistant epilepsy
      subject_extension: Vagus nerve stimulation
named_entities:
  - id: MONDO:0016693
    label: Subependymal giant cell astrocytoma
  - id: MAXO:0000447
    label: Surgical removal
  - id: CHEBI:68478
    label: everolimus
  - id: MONDO:0005550
    label: Intellectual disability (ID)
  - id: HP:0001249
    label: Intellectual disability (ID)
  - id: HP:0001250
    label: seizures
  - id: HP:0011097
    label: epileptic spasms
  - id: HP:0002121
    label: absence seizures
  - id: CHEBI:69478
    label: cannabidiol (CBD)
  - id: MONDO:0001734
    label: Tuberous Sclerosis Complex
  - id: MAXO:0001065
    label: Nephrectomy
  - id: MAXO:0000602
    label: Hemodialysis
  - id: MAXO:0000603
    label: Peritoneal dialysis
  - id: MAXO:0000600
    label: Renal replacement therapy
  - id: HP:0006772
    label: Angiomyolipomas
  - id: HP:0005584
    label: Renal cell carcinoma
  - id: HP:0001892
    label: Bleeding tendency
  - id: HP:0000083
    label: Renal insufficiency
  - id: HP:0003774
    label: end-stage renal failure
  - id: CHEBI:68481
    label: Mammalian target of rapamycin inhibitor
  - id: CHEBI:63638
    label: Vigabatrin
  - id: MONDO:0100062
    label: Infantile-Onset Developmental and Epileptic Encephalopathies (DEE)
  - id: CHEBI:26708
    label: Sodium
  - id: CHEBI:26216
    label: Potassium
  - id: MONDO:0005027
    label: epilepsy
  - id: MAXO:0000942
    label: vagus nerve stimulation (VNS)
  - id: HP:0004808
    label: multiple bilateral angiomyolipoma (AMLs)
  - id: CHEBI:9168
    label: sirolimus
  - id: HP:0001263
    label: Developmental delay
  - id: CHEBI:17234
    label: Glucose
  - id: CHEBI:15756
    label: Fatty acid (palmitate)
  - id: MONDO:0010979
    label: Tuberous sclerosis (TS); Diffuse large B-cell lymphoma (DLBCL)
  - id: CHEBI:8382
    label: Prednisone
  - id: CHEBI:480999
    label: Vinorelbine
  - id: CHEBI:4911
    label: Etoposide
  - id: CHEBI:4027
    label: Cyclophosphamide
  - id: CHEBI:64357
    label: Rituximab
  - id: CHEBI:76612
    label: Ibrutinib
  - id: MAXO:0000647
    label: chemotherapy
  - id: MONDO:0007254
    label: Breast Cancer
  - id: CHEBI:85993
    label: Palbociclib
  - id: CHEBI:31638
    label: Fulvestrant
  - id: CHEBI:41774
    label: Tamoxifen
  - id: MAXO:0001298
    label: therapy
  - id: CHEBI:8228
    label: Pioglitazone
  - id: HP:0006536
    label: Airway obstruction
  - id: HP:0000822
    label: High blood pressure
  - id: CHEBI:6367
    label: lamotrigine
  - id: CHEBI:60654
    label: valproate
  - id: CHEBI:6437
    label: levetiracetam
  - id: HP:0003394
    label: Spasms
  - id: CHEBI:24621
    label: Hormone
  - id: CHEBI:3892
    label: Adrenocorticotropic hormone (ACTH)
  - id: CHEBI:8378
    label: Prednisolone
  - id: MAXO:0000004
    label: Surgery
  - id: MAXO:0000014
    label: Radiotherapy
  - id: MAXO:0001064
    label: Mastectomy
  - id: MAXO:0000601
    label: Dialysis
  - id: HP:0031111
    label: Skin hamartoma
  - id: MONDO:0004691
    label: Autosomal dominant polycystic kidney disease
  - id: HP:0009718
    label: Subependymal giant cell astrocytomas
  - id: HP:0004755
    label: Supraventricular tachycardia
  - id: CHEBI:16796
    label: Melatonin (N-acetyl-5-methoxytryptamine)
  - id: CHEBI:23965
    label: Estradiol
  - id: CHEBI:81568
    label: Luteinizing hormone
  - id: CHEBI:16526
    label: carbon dioxide
  - id: CHEBI:49475
    label: argon
  - id: MONDO:0012084
    label: Aromatic L-amino acid decarboxylase (AADC) deficiency
  - id: MONDO:0044970
    label: Mitochondrial disease
  - id: HP:0000212
    label: Gingival hyperplasia
  - id: HP:0000230
    label: Gingivitis
  - id: MONDO:0100039
    label: CDKL5 deficiency disorder
  - id: HP:0002521
    label: hypsarrhythmia
  - id: CHEBI:50858
    label: corticosteroid
  - id: HP:0001268
    label: cognitive decline
  - id: HP:0001873
    label: Thrombocytopenia
  - id: HP:0010280
    label: Oral mucositis
  - id: HP:0000988
    label: Rash
  - id: HP:0003077
    label: Hyperlipidemia
  - id: CHEBI:231614
    label: Nivolumab
  - id: MONDO:0018874
    label: Renal Angiomyolipoma (AML)
  - id: MONDO:0100096
    label: COVID-19
  - id: HP:0012622
    label: Chronic kidney disease (CKD)
  - id: HP:0009720
    label: Facial angiofibromas
  - id: HP:0001052
    label: Port-wine stains
  - id: HP:0000989
    label: Pruritus
  - id: HP:0000238
    label: Hydrocephalus
  - id: MONDO:0002375
    label: facial angiofibromas
  - id: CHEBI:22470
    label: alpha-tocopherol
  - id: CHEBI:16199
    label: urea
  - id: HP:0002329
    label: Sleepiness
  - id: CHEBI:31413
    label: Clobazam
  - id: MAXO:0000149
    label: Healthcare transition (HCT) intervention
  - id: MONDO:0005384
    label: Focal epilepsy
  - id: MONDO:0005086
    label: Renal cell carcinoma (RCC)
  - id: MONDO:0006277
    label: Pulmonary lymphangioleiomyomatosis
  - id: CHEBI:33699
    label: mRNA
  - id: HP:0100804
    label: ungual fibromas
  - id: HP:0000752
    label: Hyperactive behavior
  - id: CHEBI:3213
    label: Bumetanide
  - id: HP:0001696
    label: Tuberous sclerosis complex
  - id: MAXO:0000448
    label: Surgical resection
  - id: MAXO:0009088
    label: Stereotactic radiosurgery
  - id: HP:0002090
    label: pneumonia
  - id: HP:0002133
    label: status epilepticus
  - id: HP:0001875
    label: neutropenia
  - id: MAXO:0000058
    label: drug treatment
